- Home
- SYBX vs IMNN Comparison
SYBX vs IMNN Comparison
Compare SYBX & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYBX
- IMNN
- Stock Information
- Founded
- SYBX N/A
- IMNN 1982
- Country
- SYBX United States
- IMNN United States
- Employees
- SYBX N/A
- IMNN N/A
- Industry
- SYBX Biotechnology: Pharmaceutical Preparations
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- SYBX Health Care
- IMNN Health Care
- Exchange
- SYBX Nasdaq
- IMNN Nasdaq
- Market Cap
- SYBX 15.9M
- IMNN 14.3M
- IPO Year
- SYBX N/A
- IMNN 1985
- Fundamental
- Price
- SYBX $1.43
- IMNN $0.81
- Analyst Decision
- SYBX Buy
- IMNN Strong Buy
- Analyst Count
- SYBX 4
- IMNN 2
- Target Price
- SYBX $15.50
- IMNN $20.50
- AVG Volume (30 Days)
- SYBX 11.4K
- IMNN 209.5K
- Earning Date
- SYBX 11-12-2024
- IMNN 11-07-2024
- Dividend Yield
- SYBX N/A
- IMNN N/A
- EPS Growth
- SYBX N/A
- IMNN N/A
- EPS
- SYBX N/A
- IMNN N/A
- Revenue
- SYBX $2,777,000.00
- IMNN N/A
- Revenue This Year
- SYBX N/A
- IMNN N/A
- Revenue Next Year
- SYBX N/A
- IMNN N/A
- P/E Ratio
- SYBX N/A
- IMNN N/A
- Revenue Growth
- SYBX 292.23
- IMNN N/A
- 52 Week Low
- SYBX $1.22
- IMNN $0.48
- 52 Week High
- SYBX $5.12
- IMNN $3.65
- Technical
- Relative Strength Index (RSI)
- SYBX 50.79
- IMNN 46.05
- Support Level
- SYBX $1.37
- IMNN $0.64
- Resistance Level
- SYBX $1.45
- IMNN $0.84
- Average True Range (ATR)
- SYBX 0.07
- IMNN 0.09
- MACD
- SYBX 0.00
- IMNN -0.00
- Stochastic Oscillator
- SYBX 31.82
- IMNN 39.09
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
About IMNN Imunon Inc.
Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.